ABOS Logo

Acumen Pharmaceuticals, Inc. (ABOS) 

NASDAQ
Market Cap
$140.71M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
402 of 775
Rank in Industry
207 of 432

Largest Insider Buys in Sector

ABOS Stock Price History Chart

ABOS Stock Performance

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Insider Activity of Acumen Pharmaceuticals, Inc.

Over the last 12 months, insiders at Acumen Pharmaceuticals, Inc. have bought $0 and sold $121,677 worth of Acumen Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Acumen Pharmaceuticals, Inc. have bought $49.68M and sold $197,005 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,161,290 shares for transaction amount of $40M was made by RA CAPITAL MANAGEMENT, L.P. () on 2023‑07‑21.

List of Insider Buy and Sell Transactions, Acumen Pharmaceuticals, Inc.

2024-01-19SalePresident and CEO
15,200
0.0253%
$3.47$52,753-12.86%
2024-01-19SaleChief Legal Officer & Corp Sec
8,933
0.0149%
$3.48$31,048-12.86%
2024-01-18SaleCFO & Chief Business Officer
4,242
0.0075%
$3.71$15,717-13.82%
2024-01-18SaleChief Medical Officer
3,124
0.0055%
$3.71$11,604-13.82%
2024-01-18SaleChief Operating Officer
2,833
0.005%
$3.73$10,555-13.82%
2023-08-17Saledirector
41,949
0.0739%
$6.49$272,334-46.80%
2023-07-21Purchase
5.16M
13.1759%
$7.75$40M-51.62%
2021-07-06Purchase
1.88M
3.8811%
$16.00$30M-67.95%
2021-07-06Purchase10 percent owner
1.06M
2.1993%
$16.00$17M-67.95%
2021-07-06Purchase10 percent owner
450,000
0.8663%
$14.88$6.7M-67.95%
2021-07-06Purchase10 percent owner
312,500
0.6468%
$16.00$5M-67.95%
2021-07-06Purchasedirector
35,000
0.0724%
$16.00$560,000-67.95%
2021-07-06Purchasedirector
6,250
0.0129%
$16.00$100,000-67.95%

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.
13043179
21.7098%
$2.3420<0.0001%
Hardie Robert D.10 percent owner
3951156
6.5765%
$2.3410<0.0001%
Sands Capital Ventures Discovery Fund III, L.P.10 percent owner
3417075
5.6876%
$2.3410<0.0001%
Manning Paul B10 percent owner
3352693
5.5804%
$2.3410<0.0001%
Stalfort John A IIIdirector
172324
0.2868%
$2.3410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$60.47M24.8514.93M0%+$00.06
Sands Capital Ventures LLC$13.84M5.693.42M0%+$03.34
Franklin Templeton Investments$13.75M5.653.4M+1.09%+$148,266.45<0.01
Millennium Management LLC$10.65M4.382.63M+75.86%+$4.59M0.01
ROCK SPRINGS CAPITAL MANAGEMENT, LP$9.32M3.832.3M0%+$00.24
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.